Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
TRDA Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Entrada Therapeutics, Inc.NASDAQ: TRDA
Gross Margin · Q1 FY2026 · quarter ended Mar 2026
Gross margin narrows to 8.0%
Gross margin was 8.0% in Q1 FY2026, down 92.0 pp from a year earlier. On a trailing-twelve-month basis it was -598.0%, down 698.0 pp year over year.
Context
- Gross margin widened in 0 of the last 2 fiscal years.
- FY2025 was the lowest level in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 83.9%
- Year-over-year change
- -16.1pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 83.9% | -16.1pp |
| FY2024 | 2024-12-31 | 100.0% | +0.0pp |
| FY2023 | 2023-12-31 | 100.0% | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
Gross Margin vs competitors
How TRDA compares with its peers on the latest reported figures
- TRDA's LTM Mar 2026 gross margin of -598.0% is the 4th highest of the 5 companies compared; the peer median is 2.2%.
- Its year-over-year change of -698.0 pp is the 4th highest of 5, against a peer median of -4.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 92.5% | -1.0 pp | +3.5 pp | |
| LTM Mar 2026 | 91.2% | -8.8 pp | -4.5 pp | |
| LTM Mar 2026 | -86.7% | +2.3 pp | +136.3 pp | |
| LTM Mar 2026 | -598.0% | -698.0 pp | — | |
| LTM Mar 2026 | -748.5% | -729.4 pp | -309.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
SGMTSagimet Biosciences Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding TRDA) | 2.2% | -4.9 pp | -0.5 pp | |
Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 129.01M | 210.78M | 25.42M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.1M |
| Gross Profit | 0 | 0 | 129.01M | 210.78M | 21.33M |
| Gross Margin | — | — | 100.0% | 100.0% | 83.9% |
| Research & Development | 35.93M | 66.61M | 99.88M | 125.31M | 142.27M |
| Selling, General & Admin | 15.2M | 30.64M | 32.29M | 38.47M | 41.05M |
| Operating Expenses | 51.13M | 97.25M | 132.18M | 163.77M | 177.32M |
| Depreciation & Amortization | 1.12M | 1.9M | 2.84M | 3.77M | 425K |
| EBITDA | (50.04M) | (90.09M) | 14.9M | 70.26M | (142.4M) |
| EBITDA Margin | — | — | 11.5% | 33.3% | -560.2% |
| Operating Income | (51.13M) | (97.25M) | (3.16M) | 47.01M | (156M) |
| Operating Margin | — | — | -2.5% | 22.3% | -613.7% |
| Interest Income | 0 | 2.63M | 15.22M | 19.47M | 0 |
| Interest Expense | 0 | 2.63M | 0 | 0 | 0 |
| Other Income / Expenses | (31K) | 2.63M | 15.22M | 19.47M | 13.17M |
| Income Before Tax | (51.16M) | (94.62M) | 12.06M | 66.49M | (142.83M) |
| Pre-Tax Margin | — | — | 9.3% | 31.5% | -561.8% |
| Income Tax Expense | 0 | 0 | 18.74M | 859K | 924K |
| Net Income | (51.16M) | (94.62M) | (6.69M) | 65.63M | (143.75M) |
| Net Margin | — | — | -5.2% | 31.1% | -565.5% |
| EPS (Basic) | (1.60) | (2.79) | (0.20) | 1.76 | (3.47) |
| EPS (Diluted) | (1.60) | (2.79) | (0.20) | 1.68 | (3.47) |
| Weighted Avg Shares | 31.22M | 31.29M | 33.05M | 37.31M | 41.37M |
| Weighted Avg Shares (Diluted) | 31.22M | 31.29M | 33.05M | 39M | 41.37M |
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$5.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.